This site is intended for U.S. Healthcare Professionals only.
For SRT-eligible patients with NYHA class II–III obstructive HCM,
18% (n=10/56) of patients taking CAMZYOS and 77% (n=43/56) taking placebo met the primary composite endpoint (remained guideline-eligible for SRT at Week 16 or chose to undergo SRT at or before Week 16). Two patients in each group decided to proceed with SRT.1
Treatment difference (95% CI): 59% (44, 74); P<0.0001
At baseline, 95% of patients were on background therapy (BB, CCB, or disopyramide either as monotherapy or in combination).2
BB=beta blocker; CCB=calcium channel blocker; CI=confidence interval; HCM=hypertrophic cardiomyopathy; NYHA=New York Heart Association; SRT=septal reduction therapy.
ADVERSE REACTIONS
Based on the safety profile from the pivotal EXPLORER-HCM trial, there were no new adverse reactions identified in VALOR-HCM.
This website is best viewed
using the horizontal display
on your tablet device.
This website is best viewed
using the vertical display
on your mobile device.
References: